Avita Therapeutics/RCEL

$8.87

-5.43%
-
1D1W1MYTD1YMAX

About Avita Therapeutics

AVITA Medical, Inc. is a commercial-stage regenerative medicine company. The Company is a provider of regenerative medicine addressing unmet medical needs in burn injuries, full-thickness skin defects, and in skin repigmentation, such as vitiligo. Its RECELL platform a single use, stand-alone, battery operated, autologous cell harvesting device containing enzymatic and buffer solutions, sterile surgical instruments, and actuators. RECELL is used for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. The platform technology of the RECELL System enables a thin split-thickness skin sample from the patient to be processed and prepared, producing an autologous cellular suspension called Spray-On Skin Cells. These Spray-On Skin Cells are prepared at the point of care in as little as 30 minutes, providing a new way to treat thermal burn wounds and full-thickness skin defects.

Ticker

RCEL

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

James Corbett

Employees

207

Headquarters

Valencia, United States

RCEL Metrics

BasicAdvanced
$241.13M
Market cap
-
P/E ratio
-$1.40
EPS
1.40
Beta
-
Dividend rate
$241.13M
1.40488
$21.70
$9.16
215.9K
7.88
7.456
81.156
81.156
-35.4%
-33.71%
-52.89%
-38.04%
4.809
4.911
4.965
45.68%
-30.97%

What the Analysts think about RCEL

Analyst Ratings

Majority rating from 8 analysts.
Buy

Price Targets

Average projection from 5 analysts.
202.14% upside
High $40.00
Low $21.00
$8.87
Current price
$26.80
Average price target

RCEL Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-49.64% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$14.1M
3.68%
Net income
$-7M
-19.54%
Profit margin
-49.64%
-22.4%

RCEL Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 25.21%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.37
-$0.41
-$0.34
-$0.28
-
Expected
-$0.25
-$0.32
-$0.44
-$0.37
-$0.45
Surprise
47.41%
26.39%
-23.42%
-25.21%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Avita Therapeutics stock?

Avita Therapeutics (RCEL) has a market cap of $241.13M as of April 19, 2024.

What is the P/E ratio for Avita Therapeutics stock?

The price to earnings (P/E) ratio for Avita Therapeutics (RCEL) stock is 0 as of April 19, 2024.

Does Avita Therapeutics stock pay dividends?

No, Avita Therapeutics (RCEL) stock does not pay dividends to its shareholders as of April 19, 2024.

When is the next Avita Therapeutics dividend payment date?

Avita Therapeutics (RCEL) stock does not pay dividends to its shareholders.

What is the beta indicator for Avita Therapeutics?

Avita Therapeutics (RCEL) has a beta rating of 1.4. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Avita Therapeutics stock price target?

The target price for Avita Therapeutics (RCEL) stock is $26.8, which is 202.14% above the current price of $8.87. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Avita Therapeutics stock

Buy or sell Avita Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing